In 2018 Douglas K. Anderson was the recipient of the US Congressional Certificate of Recognition and The University of Florida McKnight Brain Institute established the Douglas K. Anderson Facial Pain Research Program to fund future research to find cures for TN and neuropathic pain.
It was Shelly Forster’s most burning question: What is my purpose? Fighting through reconciling the logistics of her new life diagnosed with chronic pain, rock bottom became her home in 2008 – and it left her with a choice.
The purpose of this yearly update is to briefly summarize these six projects and to highlight the progress that each achieved in 2017.
Neurona and the FPRF share a bold vision to achieve pain-free disease modification. Neurona’s mission is, in part, an extension of Dr. Basbaum’s work funded by the FPRF.
Todd E. Golde, M.D., Ph.D., is executive director of the Evelyn F. and William L. McKnight Brain Institute of the University of Florida. He oversees neuroscience and neuromedicine research programs across the University of Florida campus.
Genetics Study Finds Genes That Cause Trigeminal Neuralgia Introduction by Michael Pasternak In 2012 The Facial Pain Research Foundation approved a research study to find the genes responsible for trigeminal neuralgia. While each of our Foundation’s scientific projects are valuable, the one that has been the most awesome and challenging for me has been the Genetics/DNA project.
Chris Nolze was diagnosed with brain cancer in 2007 at the young age of twelve. It was his initial diagnosis and the first of his major medical health issues.
CODA Biotherapeutics is a San Francisco based pre-clinical stage biotechnology company developing a novel therapeutic platform for the treatment of chronic pain and other severe neurological disorders.
Hate headaches? The distress you feel is not all in your -- well, head. People consistently rate pain of the head, face, eyeballs, ears and teeth as more disruptive, and more emotionally draining, than pain elsewhere in the body.
The FPRF has committed $250,000 to fund the two year research project “Evaluation of adeno-associated virus (AAV) constructs directed at pain pathway targets-a rapid approach for identification of effective therapies for trigeminal neuralgia”.
